Puma Biotechnology remains undervalued despite steady neratinib sales and a promising, though early-stage, pipeline. Learn ...

A new drug, camizestrant, shows promise in delaying progression of aggressive breast cancer. This treatment uses blood ...

The UK drugs regulator has approved Seagen’s Tukysa as a third-line treatment for HER2-positive breast cancer, shortly after it was given a green light by the European Commission. Tukysa ...

A new cancer drug candidate has demonstrated the ability to block tumor growth without triggering a common and debilitating ...

A new cancer drug candidate developed by Lawrence Livermore National Laboratory, BridgeBio Oncology Therapeutics and ...

The report provides a detailed analysis of the current breast cancer marketed drugs and late-stage pipeline drugs. BROOKLYN, ...

Daiichi Sankyo-partnered anti-HER2 drug Enhertu (trastuzumab deruxtecan) has been cleared by the European Commission for use in advanced breast cancer cases with lower levels of the HER2 biomarker ...

For $45 million upfront, Vor Bio is gaining ex-China rights to RemeGen’s telitacicept, a first-in-class recombinant ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

Vlad Vitoc, M.D., is Chairman of Board, Chief Executive Officer, and President of MAIA Biotechnology Inc. Dr. Vitoc has a ...

A new cancer drug candidate developed by Lawrence Livermore National Laboratory (LLNL), BBOT (BridgeBio Oncology Therapeutics ...